Repurposing Pirfenidone for Nonalcoholic Steatohepatitis-related Cirrhosis: A Case Series.

Abstract

We repurposed the antifibrotic drug pirfenidone-which is approved for treatment of idiopathic lung fibrosis-in a series of patients with nonalcoholic steatohepatitis-related cirrhosis. Our report demonstrates the observed improvements in necroinflammation and regression of cirrhosis with pirfenidone use for 12-weeks, associated with classical hepatic repair complex features on follow-up liver biopsies. This novel work could help stimulate further randomized trials of pirfenidone in patients with nonalcoholic steatohepatitis-related liver fibrosis or cirrhosis, for whom no recommended drug treatments exists currently.

• Authors: Cyriac Abby Philips, Guruprasad Padsalgi, Rizwan Ahamed, Rajaguru Paramaguru, Sasidharan Rajesh, Tom George, Pushpa Mahadevan, Philip Augustine
• Journal: Journal of clinical and translational hepatology (J Clin Transl Hepatol) Vol. 8 Issue 1 Pg. 100-105 (Mar 28 2020) ISSN: 2225-0719 [Print] United States
• PMID: 32274350 (Publication Type: Case Reports)
• Copyright: © 2020 Authors.